These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 30059217)

  • 1. Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation.
    Kumar K; Wang P; Sanchez R; Swartz EA; Stewart AF; DeVita RJ
    J Med Chem; 2018 Sep; 61(17):7687-7699. PubMed ID: 30059217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.
    Kumar K; Wang P; Wilson J; Zlatanic V; Berrouet C; Khamrui S; Secor C; Swartz EA; Lazarus M; Sanchez R; Stewart AF; Garcia-Ocana A; DeVita RJ
    J Med Chem; 2020 Mar; 63(6):2986-3003. PubMed ID: 32003560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication.
    Wang P; Alvarez-Perez JC; Felsenfeld DP; Liu H; Sivendran S; Bender A; Kumar A; Sanchez R; Scott DK; Garcia-Ocaña A; Stewart AF
    Nat Med; 2015 Apr; 21(4):383-8. PubMed ID: 25751815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.
    Kumar K; Man-Un Ung P; Wang P; Wang H; Li H; Andrews MK; Stewart AF; Schlessinger A; DeVita RJ
    Eur J Med Chem; 2018 Sep; 157():1005-1016. PubMed ID: 30170319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
    Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
    Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DYRK1A Kinase Inhibitors Promote β-Cell Survival and Insulin Homeostasis.
    Barzowska A; Pucelik B; Pustelny K; Matsuda A; Martyniak A; Stępniewski J; Maksymiuk A; Dawidowski M; Rothweiler U; Dulak J; Dubin G; Czarna A
    Cells; 2021 Aug; 10(9):. PubMed ID: 34571911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of β-carboline-cinnamic acid derivatives as DYRK1A inhibitors in the treatment of diabetes.
    Guan L; Li A; Song P; Su W; Zhang S; Chen J; Jiao X; Li W
    Bioorg Chem; 2024 Oct; 151():107676. PubMed ID: 39068716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Based Design and Synthesis of Harmine Derivatives with Different Selectivity Profiles in Kinase versus Monoamine Oxidase Inhibition.
    Bálint B; Wéber C; Cruzalegui F; Burbridge M; Kotschy A
    ChemMedChem; 2017 Jun; 12(12):932-939. PubMed ID: 28264138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Activity Relationships and Biological Evaluation of 7-Substituted Harmine Analogs for Human β-Cell Proliferation.
    Kumar K; Wang P; A Swartz E; Khamrui S; Secor C; B Lazarus M; Sanchez R; F Stewart A; DeVita RJ
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32340326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational Design and Identification of Harmine-Inspired, N-Heterocyclic DYRK1A Inhibitors Employing a Functional Genomic In Vivo Drosophila Model System.
    Huizar FJ; Hill HM; Bacher EP; Eckert KE; Gulotty EM; Rodriguez KX; Tucker ZD; Banerjee M; Liu H; Wiest O; Zartman J; Ashfeld BL
    ChemMedChem; 2022 Feb; 17(4):e202100512. PubMed ID: 34994084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition-The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid Harmine.
    Wurzlbauer A; Rüben K; Gürdal E; Chaikuad A; Knapp S; Sippl W; Becker W; Bracher F
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33339338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of harmine and β-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.
    Tarpley M; Oladapo HO; Strepay D; Caligan TB; Chdid L; Shehata H; Roques JR; Thomas R; Laudeman CP; Onyenwoke RU; Darr DB; Williams KP
    Eur J Pharm Sci; 2021 Jul; 162():105821. PubMed ID: 33781856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Dual Inhibitor of DYRK1A and GSK3β for β-Cell Proliferation: Aminopyrazine Derivative GNF4877.
    Liu YA; Jin Q; Ding Q; Hao X; Mo T; Yan S; Zou Y; Huang Z; Zhang X; Gao W; Wu TY; Li C; Bursalaya B; Di Donato M; Zhang YQ; Deaton L; Shen W; Taylor B; Kamireddy A; Harb G; Li J; Jia Y; Schumacher AM; Laffitte B; Glynne R; Pan S; McNamara P; Molteni V; Loren J
    ChemMedChem; 2020 Aug; 15(16):1562-1570. PubMed ID: 32613743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A natural compound harmine decreases melanin synthesis through regulation of the DYRK1A/NFATC3 pathway.
    Park CH; Kim G; Lee Y; Kim H; Song MJ; Lee DH; Chung JH
    J Dermatol Sci; 2021 Jul; 103(1):16-24. PubMed ID: 34030962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors.
    Czarna A; Wang J; Zelencova D; Liu Y; Deng X; Choi HG; Zhang T; Zhou W; Chang JW; Kildalsen H; Seternes OM; Gray NS; Engh RA; Rothweiler U
    J Med Chem; 2018 Sep; 61(17):7560-7572. PubMed ID: 30095246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization.
    Allegretti PA; Horton TM; Abdolazimi Y; Moeller HP; Yeh B; Caffet M; Michel G; Smith M; Annes JP
    Bioorg Med Chem; 2020 Jan; 28(1):115193. PubMed ID: 31757680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes.
    Kumar K; Suebsuwong C; Wang P; Garcia-Ocana A; Stewart AF; DeVita RJ
    J Med Chem; 2021 Mar; 64(6):2901-2922. PubMed ID: 33682417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic and genetic approaches define human pancreatic β cell mitogenic targets of DYRK1A inhibitors.
    Ackeifi C; Swartz E; Kumar K; Liu H; Chalada S; Karakose E; Scott DK; Garcia-Ocaña A; Sanchez R; DeVita RJ; Stewart AF; Wang P
    JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31821176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CC-401 Promotes β-Cell Replication via Pleiotropic Consequences of DYRK1A/B Inhibition.
    Abdolazimi Y; Zhao Z; Lee S; Xu H; Allegretti P; Horton TM; Yeh B; Moeller HP; Nichols RJ; McCutcheon D; Shalizi A; Smith M; Armstrong NA; Annes JP
    Endocrinology; 2018 Sep; 159(9):3143-3157. PubMed ID: 29514186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation.
    Göckler N; Jofre G; Papadopoulos C; Soppa U; Tejedor FJ; Becker W
    FEBS J; 2009 Nov; 276(21):6324-37. PubMed ID: 19796173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.